← Leaderboards
Scott M Turner
Kinemed, Inc.
$2,175,354
Attributed
$2,787,306
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $679.5K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$2,787,306 · 4
By mechanism
R44$1,903,407 · 2
R43$494,086 · 1
R21$389,813 · 1
Top collaborators
- Claire Emson2 shared
Most similar at Kinemed, Inc.
Same institution · by research overlap
- Mahalakshmi Shankaran$499,996
- Claire Emson$611,953
Others in their field
Top investigators on “Cell Proliferation”
- John M Lachin · George Washington University$118,921,924
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- David Heimbrook · Leidos Biomedical Research, Inc.$103,164,048
- Timothy J Eberlein · Washington University$49,931,668
- Deirdre R. Meldrum · University Of Washington$37,202,510
- Robert A Weinberg · Whitehead Institute For Biomedical Res$32,735,166
Research focus
Cell ProliferationStable IsotopeBiomarkerMeasurementBaseCollagenMitochondriaFibrogenesisLabelMedicalDisease ProgressionKineticsLaboratoriesMonitorClinical ResearchCessation Of LifeEvaluationExtracellular MatrixBiochemical ProcessDrug EfficacyDrug Administration Rate /DurationCicatrixDrug CandidateEffectiveness
Grant awards (7)
The application of human collagen kinetic biomarkers to anti-fibrotic drug develo$669,082
R44 · FY2010 · CA · contact PI
The application of human collagen kinetic biomarkers to anti-fibrotic drug develo$554,823
R44 · FY2009 · CA · contact PI
Kinetic Biomarker for CLL Prognosis$679,502
R44 · FY2007 · CA · contact PI
In Vivo Kinetic Biomarkers of Hepatic Toxicity$250,000
R43 · FY2005 · CA
Kinetic Biomarkers of Joint Space Molecules in OA$212,625
R21 · FY2005 · AG
In Vivo Kinetic Biomarkers of Hepatic Toxicity$244,086
R43 · FY2004 · CA
Kinetic Biomarkers of Joint Space Molecules in OA$177,188
R21 · FY2004 · AG